First Trust Advisors’s CytomX Therapeutics CTMX Stock Holding History

First Trust Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25M	Buy	599,696 +31,134	+5%	+$119K	﹤0.01%	1960
2026 Q1	$2.67M	Buy	568,562 +145,394	+34%	+$738K	﹤0.01%	1790
2025 Q4	$1.8M	Buy	423,168 +21,277	+5%	+$80.8K	﹤0.01%	1932
2025 Q3	$1.28M	Buy	+401,891	New	+$905K	﹤0.01%	2024
2019 Q2	–	Sell	-24,491	Closed	-$263K	–	2438
2019 Q1	$263K	Buy	+24,491	New	+$362K	﹤0.01%	2298
2018 Q4	–	Sell	-95,805	Closed	-$1.77M	–	2415
2018 Q3	$1.77M	Sell	95,805 -40,833	-30%	-$930K	﹤0.01%	1731
2018 Q2	$3.12M	Buy	+136,638	New	+$3.49M	0.01%	1363

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

First Trust Advisors's CTMX Position: Q2 2026 in Review

First Trust Advisors increased its CytomX Therapeutics (CTMX) stake by 5.5% in Q2 2026, buying an estimated $119K and bringing the position to 599,696 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1960.

First Trust Advisors first reported a position in CTMX in Q2 2018 and has held it in 7 quarters since. The position peaked at $3.12M in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

First Trust Advisors held 599,696 shares of CytomX Therapeutics worth $2.25M as of Q2 2026.
First Trust Advisors bought 31,134 CytomX Therapeutics shares in Q2 2026, an estimated $119K.
CytomX Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1960 holding.
First Trust Advisors first reported a position in CytomX Therapeutics in Q2 2018 and has held it in 7 quarters since.
First Trust Advisors's CytomX Therapeutics position peaked at $3.12M in Q2 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.